ClinicalTrials.Veeva

Menu

Double-blind Study to Assess effectIveness of Pectoral Nerves Block After Breast Surgery on Piritramide Consumption (DESIGN)

F

Free University of Brussels (ULB)

Status and phase

Completed
Phase 3

Conditions

Locoregional Analgesia in Breast Surgery

Treatments

Drug: Clonidine
Drug: Ropivacaine
Drug: Sodium Chloride

Study type

Interventional

Funder types

Other

Identifiers

NCT02655965
CE2483 (Other Identifier)
2015-005574-38 (EudraCT Number)
IJB-SUR-DESIGN-2015

Details and patient eligibility

About

The aims of this study is to compare the effectiveness of pecs block associated to a general anesthesia in terms of Piritramide consumption compared with a general anaesthesia alone and the chronic pain incidence in patients that undergoing either a lumpectomy or a mastectomy associated with axillary dissection This is a double-blind, placebo controlled study that will randomise breast cancer subjects in 1:1 ratio to receive a "pecs block" of Ropivacaine 3.5 mg/ml and Clonidine 5 µg/ml (arm A) versus placebo (arm B).

Full description

This is a double-blind study that will randomise breast cancer subjects in 1:1 ratio to receive a "pecs block" of 10 ml of Ropivacaine 3.5 mg/ml and Clonidine 5 µg/ml injected between pectoral muscles and 20 ml between the muscles pectoralis minor and serratus anterior (arm A) versus 10 ml of placebo (NaCl 0.9%) injected between pectoral muscles and 20 ml between the muscles pectoralis minor and serratus anterior (arm B). The pecs block will inject just before the surgery.

Subjects will receive a nausea and vomiting prophylaxy depending on Apfel score After surgery, the two intervention groups will receive before waking a dose of Paracetamol (1 g) and Diclofenac (75 mg), if they present no contraindications and a dose of 0.05 mg/kg Piritramide .

In the recovery room the two groups will benefit from a Patient Controlled Intravenous Analgesia (PCIA) pump - Piritramide allowing them to control their analgesia, which will be stopped at 24 hours postoperatively.

Enrollment

54 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age ≥18 years old

  2. Female

  3. Subjects undergoing either a conservative or non-conservative breast surgery associated with axillary dissection

  4. ASA score ≤ 3

  5. Completion of all necessary screening procedures within 30 days prior to randomisation

  6. Adequate Renal Function including: Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or estimated creatinine clearance ≥ 60 ml/min as calculated using the method standard for the institution

  7. Adequate Liver Function, including all of the following parameters:

    1. Aspartate and Alanine Aminotransferase (AST and ALT) ≤ 1.5 x ULN If Aspartate and Alanine aminotransferase (AST and ALT) are > 1.5 x ULN, total serum bilirubin should be assessed and must be ≤ 1.5 x ULN unless the patient has documented Gilbert Syndrome
    2. Alkaline phosphatase ≤ 2.5 x ULN
  8. Signed informed consent

  9. Willingness and ability to comply with the study scheduled visits, treatment plans, laboratory tests and other procedures

Exclusion criteria

  1. Any illness or medical condition that is unstable or could jeopardize the safety of the patient or her compliance with study requirements
  2. Allergy to local anaesthetics
  3. Known allergy or hypersensitivity to Paracetamol, Diclofenac, Piritramide or excipients
  4. Coagulopathy or taking oral anticoagulant/ antiaggregant within 7 days prior to surgery
  5. BMI> 35 kg / m2
  6. Infection near the puncture site
  7. Inability to understand the pain assessment scales (VAS and McGill questionnaire)
  8. Severe hepatic impairment: elevated transaminases with factor V ≤ 50%
  9. Severe heart failure: NYHA classification III or IV and/or LVEF < 50%
  10. Pregnant or lactating women
  11. Concurrent treatment with daily basis chronic opiate type painkillers not ended 1 month prior surgery
  12. Scheduled breast reconstruction at the time of surgery
  13. Metastatic subjects
  14. Subjects with breast implants
  15. Patients that require bilateral mastectomy or bilateral lumpectomy

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

54 participants in 2 patient groups, including a placebo group

Ropivacaine + Clonidine
Experimental group
Description:
A "pecs block" of Ropivacaine 3.5 mg/ml and Clonidine 5 µg/ml will be injected to the patients prior surgery. 10 ml of the drug combination will be injected between pectoral muscles and 20 ml of the drug combination will be injected between the muscles pectoralis minor and serratus anterior. After surgery, subjects in both arms will receive one dose of Paracetamol (1g) and Diclofenac (75 mg) and one dose 0.05 mg/kg Piritramide as well as PCIA (Patient Controlled Intravenous Analgesia)-Piritramide for 24 hrs post-surgery.
Treatment:
Drug: Ropivacaine
Drug: Clonidine
Sodium Chloride
Placebo Comparator group
Description:
A "pecs block" of Placebo (Sodium Chloride 0.9%) will be injected to the patients prior surgery. 10 ml of the Sodium chloride solution will be injected between pectoral muscles and 20 ml of the Sodium chloride solution will be injected between the muscles pectoralis minor and serratus anterior). After surgery, subjects in both arms will receive one dose of Paracetamol (1g) and Diclofenac (75 mg) and one dose 0.05 mg/kg Piritramide as well as PCIA (Patient Controlled Intravenous Analgesia)-Piritramide for 24 hrs post-surgery.
Treatment:
Drug: Sodium Chloride

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems